US biotech to submit new psoriasis treatment to the FDA in summer
Dermavant Sciences has presented an interim analysis of phase III results from trial involving new treatment for plaque psoriasis, which will form basis for FDA new drug application.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
In 2022, US skin doctors may get their hands on a new tool for treating patients with plaque psoriasis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Almirall acquires rights to new psoriasis drug in Europe
For subscribers
.jpg&w=384&q=75)
